The Prostate Center has been established in a multidisciplinary fashion involving the Division of Urology, Department of Radiology, Department of Radiation Oncology and Department of Pathology. The AUBMC, Division of Urology has pioneered the concept of PSA screening for early detection of prostate cancer along US accepted standards and guidelines. The educational programs introduced to expand the awareness of PSA and prostate cancer where initiated as part of the American College of Surgeons Lebanese Chapter meeting in October 1998, and the Middle East Medical Assembly Meeting in April 1998. These heralded the campaigns that were later initiated by the Lebanese Urologic Society in Association with the Lebanese Ministry of Health screening for prostate cancer in 1999, in which AUB was a major player. Currently, the Division of Urology at AUB is the most active center managing prostate diseases in the Middle East, and has pioneered the procedure of Radical Retropubic
Prostatectomy (complete surgical ablation of the prostate) for
the management of organ-confined cancer of the prostate in the
area. Our work in the field has resulted in several abstracts
that were presented in regional and international meetings. We
have been also involved as moderators and visiting professors in
the region to present our work on prostate specific antigen and
its use for the early detection in prostate cancer, as well as
surgical techniques and modifications in performing the radical
retro pubic prostatectomy (Publications).
Currently, we are focusing on the management of state T2 disease (cancer of the prostate with extension into the prostatic capsule and seminal vesicle) in conjunction with the Department of Radiation Oncology. This has been introduced with the possibility of neo-adjuvant hormonal therapy in combination with radiotherapy following surgical ablation of the prostate. Young patients who meet criteria of clinical T3 disease are offered the option of radical retropubic prostatectomy with adjuvant hormonal ablation-radiation therapy. These high-risk patients are also offered a novel protocol of neoadjuvant chemotherapy before radical prostatectomy. In addition, we are looking at introducing Cryotherapy and Brachytherapy, and are working closely on treatment protocols with the University of Massachusetts Medical Center, Division of Urology and the Massachusetts Prostate Cancer Research Institute.
Since 1998 the number of prostate cancer surgeries has quadrupled. We anticipate that radical prostatectomies will continue to increase along with other therapeutic interventions at our Medical Center. The increased awareness of prostate cancer and its early diagnosis is currently seen throughout the Middle East.